Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Carcinoma, Renal Cell 4Leukemia, Myeloid, Chronic-Phase 3Kidney Neoplasms 3Neoplasm Metastasis 2Lymphoma 2Leukemia 2Hepatitis B, Chronic 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Meningeal Carcinomatosis 1

Interventions

AZD 6244 9Lovastatin 5Deoxycholic Acid 4trametinib 3Lasers, Solid-State 3mirdametinib 2fludarabine 2Transcranial Direct Current Stimulation 2Sirolimus 2Polidocanol 2Magnetic Resonance Imaging 2Lasers 2Lamotrigine 2Inhalation 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1peginterferon alfa-2b 1gadolinium compound P760 1fludarabine phosphate 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1X-Rays 1Vitamin D 1Vincristine 1Vinblastine 1Temozolomide 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neurofibromatosis 1 × peginterferon alfa-2b × Clear all
NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Corewell Health West

Phase 2 Completed
9 enrolled 9 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡